



## Study Advocacy Factsheet

### The ESTRELLA Study

The ESTRELLA study is for people with liver disease from alpha-1 antitrypsin deficiency (A1ATD). The study is to find out whether a study drug, which is designed to stop liver disease from progressing, is safe and does not cause severe side effects.

 <b>Participation Requirements</b>	<ul style="list-style-type: none"><li>• 18 to 70 years of age</li><li>• Confirmed diagnosis of A1ATD and liver disease</li><li>• Able to have 2 liver biopsies</li></ul>
 <b>Study Drug</b>	<ul style="list-style-type: none"><li>• Injection (by needle into the thigh or abdomen)</li><li>• 2 to 12 injections, each at least 1 month apart over 24 to 48 weeks</li><li>• Compared to placebo, which has no active ingredients</li><li>• Participants have a greater chance of receiving the study drug than placebo</li></ul>
 <b>Number of Participants</b>	<ul style="list-style-type: none"><li>• 30-54 participants</li></ul>
 <b>Length</b>	<ul style="list-style-type: none"><li>• Approximately 1-2 years</li></ul>
 <b>More Information</b>	<ul style="list-style-type: none"><li>• <a href="http://estrellastudy.com">estrellastudy.com</a></li></ul>